Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mandy Jackson

Mandy Jackson is the US West Coast Editor for Scrip Intelligence. Mandy reports on daily biopharma news and regularly interviews everyone from big pharma CEOs to biotech startup founders about the business strategy behind their finance, dealmaking and drug development news. She also has an interest in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, and business development trends. Mandy has been a business news reporter for more than 15 years, covering biotech and pharma companies, biotech law and commercial real estate. She is based in San Diego, California – the venue for many medical and biopharma industry meetings.

Latest From Mandy Jackson

Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC

Adagrasib may carve out a niche as the superior drug in colorectal cancer, but lung cancer – where Lumakras already is approved – is a larger market where Amgen has a big lead.

Clinical Trials Strategy

Finance Watch: 2021 Now Has More IPOs Than 2020, But With $3.2bn Less

Public Company Edition: It took 256 days for 2021 to surpass the 2020 record of 86 biopharma initial public offerings in the US in one year. Also, Procaps raised $115m ahead of its SPAC merger and aTyr and bluebird raised $75m each.

Financing Innovation

First Lumakras Combo Data Show Boosted Efficacy For Amgen Drug In CRC

Amgen’s KRAS G12C inhibitor in combination with the company’s Vectibix generated a 27% overall response rate, nearly tripling the responses seen with Lumakras monotherapy in colorectal cancer.

Clinical Trials Personalized Medicine

Amylyx Will Submit ALS Drug For Approval In The Coming Months

After discussions with the US FDA, the company determined it can file AMX0035 based on Phase II/III results and interim Phase III data. Amylyx is sticking with its go-it-alone strategy for global commercialization.

Drug Approval Standards Neurology

Finance Watch: Lightstone Ventures Closes $375m Fund To Back Early Stage Biotechs

Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.

Financing Innovation

Working Toward A Cure: Janssen’s Multiple Myeloma Strategy

Janssen’s Mark Wildgust explained how the Johnson & Johnson subsidiary is pushing forward with novel therapeutics and combination regimens with the goal of eliminating myeloma in the first line.

Strategy Clinical Trials
See All
UsernamePublicRestriction

Register